A Randomised Non-inferiority Trial with Nested PK to Assess DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 25 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dolutegravir/lamivudine (Primary) ; Integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms D3 (penta21)

18 Nov 2024 Planned End Date changed from 31 Jul 2025 to 30 Sep 2025.
18 Nov 2024 Planned primary completion date changed from 15 Sep 2024 to 30 Sep 2025.
01 Jul 2024 Design, published in the Contemporary Clinical Trials

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com